ABBV vs PFE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PFE |
| Current Price |
$261.70 |
$27.64 |
| Fair Value Estimate |
$259.04 |
$30.94 |
| Upside to Fair Value |
-1.0%
|
+12.0%
|
| Market Cap |
$462.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
17.4x
|
| Price / Sales |
7.2x
|
2.5x
|
| Price / FCF |
23.6x
|
14.3x
|
| Revenue Growth YoY |
+10.2%
|
+2.6%
|
| Gross Margin |
71.5%
|
71.3%
|
| Operating Margin |
29.3%
|
25.1%
|
| Return on Equity |
-136.5%
|
4.9%
|
| Dividend Yield |
2.61% |
6.22% |
| FCF Yield |
4.25%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
ABBV |
PFE |
| Zone Low |
$194.28 |
$23.21 |
| Zone High |
$220.18 |
$26.30 |
| In Buy Zone? |
No
|
No
|